Raily Aesthetic Medicine Delays Utilization of Proceeds Amid COVID-19 Challenges
Raily Aesthetic Medicine International Holdings Limited (HK:2135) has announced a delay in utilizing HK$8.6 million for organic growth due to difficulties in finding suitable locations in Shanghai amid COVID-19. Additionally, HK$7.6 million from a Rights Issue remains unutilized as the company prepares for product registration. The funds are expected to be used by the end of 2025 and March 2026, respectively. The company focuses on expanding its aesthetic medical services in China and will keep stakeholders updated on progress.
Raily Aesthetic Medicine International Holdings Limited ( (HK:2135) ) has provided an update.
Raily Aesthetic Medicine International Holdings Limited announced a delay in utilizing HK$8.6 million of its proceeds intended for organic growth due to challenges in identifying suitable locations in Shanghai during the COVID-19 pandemic. Additionally, HK$7.6 million from the Rights Issue remains unutilized as the company prepares for the registration of aesthetic medical equipment products. The company plans to use these funds by the end of 2025 and March 2026, respectively, and will keep stakeholders informed of any progress.
More about Raily Aesthetic Medicine International Holdings Limited
Raily Aesthetic Medicine International Holdings Limited operates in the aesthetic medicine industry, focusing on providing aesthetic medical services and products. The company aims to expand its presence in China, particularly through establishing aesthetic medical institutions and registering medical equipment products.
Average Trading Volume: 530,727
Technical Sentiment Signal: Sell
Current Market Cap: HK$64.62M
Find detailed analytics on 2135 stock on TipRanks’ Stock Analysis page.
